Albumin-bound paclitaxel

Drug Profile

Albumin-bound paclitaxel

Alternative Names: ABI-007; Abraxane; Coraxane; Coroxane; Nab-Paclitaxel; Systemic nanoparticle albumin-bound paclitaxel

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abraxis BioScience
  • Developer Abraxis BioScience; Australian and New Zealand Urogenital and Prostate Cancer Group; Cambridge University Hospitals; Cancer Research UK; Celgene Corporation; Columbia University; Eli Lilly; Genentech; M. D. Anderson Cancer Center; Mayo Clinic; NCIC Clinical Trials Group; New York University School of Medicine; Oncosur; PrECOG; Southeastern Gynecologic Oncology; Taiho Pharmaceutical; University of California, Davis; University of Iowa; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Small cell lung cancer; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Bladder cancer; Ovarian cancer; Prostate cancer
  • Discontinued Coronary artery restenosis; Peripheral arterial disorders; Vascular restenosis

Most Recent Events

  • 04 Aug 2017 NICE publishes guidance recommending albumin-bound paclitaxel for routine National Health Service use for Pancreatic cancer in the UK after the company agreed a confidential price discount and provided more evidence on its effectiveness
  • 01 Jul 2017 Celgene terminates phase II trial in Pancreatic cancer (First-line therapy, Late-stage disease, Combination therapy, Inoperable/Unresectable) in United Kingdom, due to poor accrual (NCT02124369)
  • 03 Jun 2017 Safety and efficacy data from a phase II trial in Cholangiocarcinoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top